AdBlock rilevato
We have detected an active AdBlocker!

Please disable your AdBlocker or add this site to your exceptions.

Our advertising is not intrusive and will not disturb you.
It allows the site to sustain itself, grow, and provide you with new content.

You will not be able to access the content as long as AdBlocker remains active.
After disabling it, this window will close automatically.

Sfondo Header
L'angolo del dottorino
Search the site... Advanced search


POST-INFARCTION PERICARDITIS

Acute myocardial infarction (AMI) can be complicated by several forms of pericarditis, distinguished by their timing and pathogenetic mechanism.


In addition to cardiac rupture with acute pericardial hemorrhage and cardiac tamponade, the main types of post-infarction pericarditis are:

Diagnosis:

both forms are identified by ECG, which may show diffuse ST-segment changes (superimposed on those of AMI), and by echocardiography, which is useful for assessing the presence of pericardial effusion.

Treatment:

management is based on NSAIDs (ibuprofen or aspirin) and colchicine to reduce the risk of recurrence. Corticosteroids are reserved for resistant cases or those with multiple recurrences.


TRAUMATIC PERICARDITIS

Traumatic pericarditis develops following trauma involving the pericardium, predominantly of hemorrhagic type.

Main causes:

Clinical manifestations:

Traumatic pericarditis generally presents with late-onset chest pain (3-4 weeks after trauma), associated with high fever, leukocytosis and elevated ESR. In severe cases, it may progress to constrictive pericarditis.

Diagnosis:

Treatment:


DRUG-INDUCED PERICARDITIS

Certain drugs can induce pericarditis as an adverse effect, either through a hypersensitivity mechanism or a direct toxic effect on the pericardium.

Most frequently implicated drugs:

Clinical manifestations:

Symptoms vary depending on the drug and pathogenetic mechanism. The autoimmune form (procainamide, hydralazine) may be insidious and chronic, while acute toxic reactions (penicillin, phenylbutazone) tend to present with fever and serous or hemorrhagic pericardial effusion.

Diagnosis:

Treatment:


    References
  1. Imazio M, et al. Management of pericardial diseases. Nat Rev Cardiol. 2020;17(11):693-706.
  2. Adler Y, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases. Eur Heart J. 2015;36(42):2921-2964.
  3. LeWinter MM. Clinical practice: pericarditis. N Engl J Med. 2014;371(25):2410-2416.
  4. Maisch B, et al. Pericardial diseases: new insights and unresolved issues. Heart Fail Rev. 2018;23(1):3-14.
  5. Tsang TS, et al. Diagnosis and management of pericardial effusion. Mayo Clin Proc. 2002;77(4):406-413.
  6. Troughton RW, et al. Medical therapy in pericardial disease: an update. Circulation. 2018;137(7):743-754.
  7. Brucato A, et al. Recurrent pericarditis: current perspectives. Clin Cardiol. 2022;45(3):249-258.
  8. Little WC, et al. Pericardial disease. Circ Res. 2015;116(12):1940-1952.
  9. Chow LH, et al. Acute and recurrent pericarditis: modern diagnostic and management strategies. Curr Cardiol Rep. 2021;23(8):95.
  10. Spodick DH. The pericardium: a comprehensive textbook. Marcel Dekker. 1997;1st ed:1-600.